Sermorelin is typically explored as a truncated analog associated with growth hormonereleasing pathways, while GHRP-2 is examined as a separate peptide that may interact with additional upstream regulatory receptors
Evidence Limitations and Unanswered Questions The main evidence limitations for GHK-Cu are uneven human data, formulation differences, limited injectable safety information, small topical skin studies, indirect hair evidence, and uncertain long-term outcomes [2], [6], [7], [8]
For example, if you are currently taking Ozempic for type 2 diabetes management, you can switch to FDA-approved medications for diabetes
If youre interested in exploring surgical options, your health care provider can refer you to a bariatric specialist, or you can reach out directly to the Bariatrics Center at Nebraska Medicine